US Coverage
Law360 | The Practice of Law
State Specific Coverage
Law360 Authority | Deep News & Analysis
Boehringer Ingelheim Pharmaceuticals, Inc., Petitioner v. Department of Health and Human Services, et al.
Case Number:
25-799
Court:
Nature of Suit:
Firms
Companies
Government Agencies
Sectors & Industries:
-
May 19, 2026
What's Next After High Court's Medicare Drug Pricing Pass
As the pharmaceutical industry grapples with the U.S. Supreme Court's refusal to hear about the legality of Medicare drug pricing negotiations, experts say to expect a pivot in and outside the courtrooms.
-
May 18, 2026
High Court Spurns Pharma Challenges To IRA Drug Price Talks
The U.S. Supreme Court rejected six petitions Monday from pharmaceutical giants seeking to bring down the Medicare drug price negotiations established as part of the Inflation Reduction Act three years ago.
-
April 09, 2026
US Again Urges High Court To Back Drug Price Program
The administration of President Donald Trump again urged the Supreme Court not to hear a challenge to the Medicare drug price negotiation program, arguing against a constitutional challenge brought by Boehringer Ingelheim that drug companies aren't forced to accept lower prices because they can choose not to participate.
-
April 04, 2026
Case-By-Case Guide As Justices Eye Landmark Pharma Law
Drugmakers and prominent allies are inundating the U.S. Supreme Court with calls to scrutinize Medicare's new power to slash payments by tens of billions of dollars, and the justices look poised to take up or turn down a fistful of legal challenges in one fell swoop.
-
January 12, 2026
The Curious, Very Long Delay In A Pioneering Drug Prices Suit
When Merck & Co. launched a fiery challenge to Medicare's landmark drug price negotiations, it blazed a trail for many similar suits. But 31 months later, the challenge is stalled where it started as Merck begs for a ruling, other suits speed along the path it created and huge costs now seem unavoidable.